Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$18.83 USD
-0.88 (-4.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $18.82 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Beam Therapeutics Inc. has a PEG ratio of 7.79 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.09.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BEAM 18.83 -0.88(-4.46%)
Will BEAM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
Innovation ETF (ARKK) Hits New 52-Week High
3 Promising Genomics Stocks to Keep an Eye On in 2025
Other News for BEAM
Cathie Wood Starts This Volatile Week with $13M Buy and a Key Sell-Off
Cathie Wood's ARK Investment buys 659K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 29K shares of Beam Therapeutics today
Cathie Wood's ARK Investment buys 55K shares of Beam Therapeutics today
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies